NEUROBIOLOGICAL SIGNS PHASE III AGREEMENTS

Richmond's Neurobiological Technologies signed deals with two other companies to make and package its ischemic stroke drug for upcoming Phase III trials.

Neurobiological Technologies expects to start the trials for Viprinex later this year. The active ingredient for the drug is ancrod, made from venom of the Malayan pit viper. It will be prepared by German company Nordmark Arzneimittel Gmbh.

Baxter Pharmaceutical Solutions in Bloomington, Ind., will fill and package the drug for the trials, and will also make the placebo used in the tests.

Neurobiological did not disclose the financial terms of the contracts.